학술논문

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors
Document Type
Article
Source
In: Cancer. (Cancer, 15 August 2017, 123(16):3080-3087)
Subject
Language
English
ISSN
10970142
0008543X